Key statistics
As of last trade, Conduit Pharmaceuticals Inc (ZK7:FRA) traded at 0.0905, 29.29% above the 52 week low of 0.07 set on Nov 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0905 |
---|---|
High | 0.0905 |
Low | 0.0905 |
Bid | 0.0925 |
Offer | 0.104 |
Previous close | 0.128 |
Average volume | 11.08k |
---|---|
Shares outstanding | 102.85m |
Free float | 53.35m |
P/E (TTM) | -- |
Market cap | 11.10m USD |
EPS (TTM) | -0.1708 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:11 GMT.
More ▼
Announcements
- Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
- Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
- Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline
- Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes
- Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders
- Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments
- Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
- Conduit Pharmaceuticals to Join Russell 3000® Index
- Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
More ▼